1xbet모바일 Pharmaceutical Co., Ltd.

1xbet모바일 Pharmaceutical Co., Ltd., and its indirect subsidiary 1xbet모바일 Pharmaceutical Development & Commercialization, Inc. (1xbet모바일), announce that the latter has been awarded a grant for up to US million from the Bill & Melinda Gates Foundation to advance clinical development of 1xbet모바일's investigational compound to treat tuberculosis (TB), OPC-167832, in combination with delamanid as the backbone of a pan-TB regimen in line with the World Health Organization's (WHO) Target Regimen Profiles (TRP).

The WHO TRPs are meant to assist drug developers in identifying important drug regimen features and aligning these with patient and programmatic needs at a country level. A pan-TB regimen could revolutionize TB treatment by 1xbet모바일fering an effective, 3-or-4 drug, fully oral regimen with an acceptable safety pr1xbet모바일ile that could be administered to almost all patients with active TB regardless 1xbet모바일 their drug resistance pr1xbet모바일ile.

In 2017, 1xbet모바일 completed a phase 1, single-ascending-dose study of OPC-167832. OPC-167832 is also being evaluated in pre-clinical studies using the hollow fiber system at the Baylor Scott & White Research Institute and in additional non-clinical studies in collaboration with the U.S. National Institutes of Health / National Institute of Allergy and Infectious Diseases.

The grant will allow 1xbet모바일 to further evaluate OPC-167832 as part of a novel trial design combining multiple-ascending-dose and early-bactericidal-activity studies for evaluation in drug-susceptible TB patients, scheduled to begin in the fourth quarter of 2018. It will also allow 1xbet모바일 to explore a combination of OPC-167832 plus delamanid for future evaluation of pan-TB regimens.

About 1xbet모바일167832

OPC-167832 is an anti-TB compound discovered and currently under investigation by 1xbet모바일. It inhibits the enzyme DprE1, which is connected to synthesis involving mycobacterial cell walls. This is a different mechanism of action from other currently available anti-TB drugs.

About Delamanid

Delamanid inhibits the synthesis 1xbet모바일 mycolic acid, an essential component 1xbet모바일 mycobacterial cell walls. Regulatory approval has been received in the EU, Japan, South Korea, Hong Kong, the Philippines, Turkey and India where it is marketed as Deltyba^™.